News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
BioSpace News Archive
Browse BioSpace’s published news and press releases by year, month, and day.
143 Results
Year
2005 (24679)
2006 (34770)
2007 (39687)
2008 (39410)
2009 (42118)
2010 (39616)
2011 (38383)
2012 (38416)
2013 (36268)
2014 (39672)
2015 (44432)
2016 (38329)
2017 (37188)
2018 (39119)
2019 (51334)
2020 (57663)
2021 (58720)
2022 (53927)
2023 (42564)
2024 (37441)
2025 (33090)
2026 (22766)
Month
January (2433)
February (2868)
March (3029)
April (3116)
May (3356)
June (2727)
July (2287)
August (2493)
September (457)
Day
1 (26)
2 (174)
3 (177)
4 (143)
5 (222)
6 (34)
9 (203)
10 (137)
11 (95)
12 (124)
13 (105)
15 (21)
16 (103)
17 (104)
18 (170)
19 (133)
20 (75)
22 (7)
23 (133)
24 (158)
25 (111)
26 (117)
27 (109)
30 (214)
31 (134)
Year
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Month
January
February
March
April
May
June
July
August
September
Day
1
2
3
4
5
6
9
10
11
12
13
15
16
17
18
19
20
22
23
24
25
26
27
30
31
Podcast
UniQure’s Delay, REGENXBIO’s Rejection Explained, Sarepta’s Ingram Steps Down, More
UniQure and REGENXBIO are both dealing with FDA setbacks for their respective gene therapies, as regulatory experts question the FDA’s decision-making processes; CBER director Vinay Prasad is under probe for allegedly fostering a toxic workplace; Sarepta CEO Doug Ingram is stepping down after several years of tumult at the top of the muscular dystrophy–focused company; and Eli Lilly again tops Novo Nordisk in a weight loss trial.
March 4, 2026
·
1 min read
·
Heather McKenzie
Press Releases
CORRECTING and REPLACING Scholar Rock Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
March 4, 2026
·
15 min read
Press Releases
HSS Presents New Findings Impacting Pediatric Orthopedic Care Recommendations at AAOS Annual Meeting
March 4, 2026
·
6 min read
Press Releases
Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial Results
March 4, 2026
·
14 min read
Press Releases
Dentsply Sirona to Participate in the Leerink Partners Global Healthcare Conference 2026
March 4, 2026
·
1 min read
Press Releases
Oculis Reports Q4 and Full Year 2025 Financial Results and Provides Company Update
March 4, 2026
·
11 min read
Press Releases
Sana Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
March 4, 2026
·
23 min read
Press Releases
Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare Conference
March 4, 2026
·
1 min read
Press Releases
Lexicon Pharmaceuticals to Participate in Three Upcoming March 2026 Investor Conferences
March 4, 2026
·
1 min read
Press Releases
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 3, 2026
March 4, 2026
·
1 min read
Previous
3 of 15
Next
